PGRMC1 and endometrial cancer: Consistent with previously reported PGRMC1-dependent anti-mitotic effects of P4 in Ishikawa endometrial cancer cells [36] and MDA-MB-231 breast cancer cells [47], incubation of cells in 1 μM P4 retarded cell proliferation of all cells over-expressing a PGRMC1-HA protein (WT, DM or TM), but not of MP cells relative to non-P4-treated control cells (Fig. 2a).